Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Atrasentan vs Docetaxel and Placebo in Advanced Hormone Refractory Prostate Cancer
NCT00134056Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2006
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atrasentan in prostate cancer (PCa), sponsored by SWOG Cancer Research Network. Started Aug 2006; status: completed.
02
Drugs
atrasentan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00134056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134056.